NVO — Novo Nordisk A/S Share News
0.000.00%
Last trade - 00:00- $175.03bn
- $189.31bn
- DKK309.06bn
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial
China's vice commerce minister meets foreign businesses
Europe Research Roundup: Atalaya Mining Copper, Givaudan, SAP
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients (updated)
Novo says its next-gen obesity drug tops Lilly rival in late-stage study
Brief: Novo: CagriSema Shows Greater Weight Loss Than Tirzepatide In Trial
Wegovy maker Novo shares slump as management grilled on pricing, M&A (updated)
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
Novo Nordisk presents 2030 goals, shares slump
Brief: Novo Nordisk Aims To Deliver 2026-30 Revenue CAGR In Line With Industry Peers
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugs
Anthropic quietly sets up biology lab as it ramps AI drug program
Brief: Novo's Sogroya Gets Positive CHMP Opinion In Europe For Children With ISS
Brief: CHMP Recommends Granting Marketing Authorisation For Frehemgo, Vaxrabeo, Adcomfo & Pebrilzo
Anthropic quietly sets up biology lab as it ramps AI drug program
All 50 states sign up for Trump's Medicaid most-favored-nation plan (updated)
Sandoz seen rising after it secures Canada approval for generic GLP-1 shot
Brief: CHMP Recommends EU Approval Of Novo's Frehemgo